Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 4/20 | 0.70 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.65 |
| ▸ | RAB9A | P51151 | 3/20 | 0.65 |
| ▸ | MEN1 | O00255 | 3/20 | 0.65 |
| ▸ | NPC1 | O15118 | 2/20 | 0.65 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.65 |
| ▸ | THRB | P10828 | 1/20 | 0.62 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.61 |
| ▸ | HPGD | P15428 | 1/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.60 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.60 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.60 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.59 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29560373 | 1.00 | EPHX2 (0.70) | EPHX2KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL9830559 | 0.95 | EPHX2 (0.68) | EPHX2KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL10102744 | 0.94 | CYP2C9 (0.69) | EPHX2KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL19246323 | 0.94 | CYP2C9 (0.69) | EPHX2KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL9829860 | 0.94 | CYP2C9 (0.69) | EPHX2KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL29775260 | 0.91 | RAB9A (0.68) | EPHX2KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL1520738 | 0.91 | RAB9A (0.68) | EPHX2KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL9809561 | 0.89 | RAB9A (0.76) | EPHX2KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL17822214 | 0.89 | EPHX2 (0.75) | EPHX2KMT2ARAB9AMEN1NPC1 | |
| SCHEMBL14290329 | 0.88 | RAB9A (0.67) | EPHX2KMT2ARAB9AMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 596 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250375429-A1 | OBLIGATE PAIRING OF ORTHOSTERIC AND NON-ORTHOSTERIC GABA LIGANDS IN PHARMACEUTICAL FORMULATIONS | SMARTER NOT HARDER, INC. (US) | 2025-12-11 | — | — | US | claimed |
| US-20250367206-A1 | 1-METHYLXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2025-12-04 | — | — | US | claimed |
| CN-120025976-A | Method for differentiating hematopoietic stem/progenitor cells into granulocytes | 苏州血霁生物科技有限公司 | 2025-05-23 | — | — | CN | claimed |
| US-20250163379-A1 | METHOD FOR DIFFERENTIATING HEMATOPOIETIC STEM/PROGENITOR CELLS INTO NK CELLS | HEMACELL BIOTECHNOLOGY INC. (CN) | 2025-05-22 | — | — | US | claimed |
| US-20250019345-A1 | NEW CANNABINOID-GABAPENTINOID CONJUGATES AND USES THEREOF | LONDON PHARMACEUTICALS AND RESEARCH CORPORATION (CA) | 2025-01-16 | — | — | US | claimed |
| US-12161695-B2 | GABA A receptor agonists for treatment of disorders influenced by dysfunction BETA cells | DIAMYD MEDICAL AB (SE) | 2024-12-10 | — | — | US | claimed |
| CN-118786209-A | Method for differentiating hematopoietic stem/progenitor cells into NK cells | 苏州血霁生物科技有限公司 | 2024-10-15 | — | — | CN | claimed |
| EP-4430023-A1 | NEW CANNABINOID-GABAPENTINOID CONJUGATES AND USES THEREOF | London Pharmaceuticals and Research Corporation (CA) | 2024-09-18 | — | — | EP | claimed |
| EP-4376846-A1 | BIOACTIVE COMPOSITIONS AND METHODS OF USE THEREOF | PX ING, LLC (US) | 2024-06-05 | — | — | EP | claimed |
| EP-4319759-A1 | 1-METHYLXANTHINE-BASED BIOACTIVE COMPOSITION AND METHOD OF USE THEREOF | Ingenious Ingredients, LP (US) | 2024-02-14 | — | — | EP | claimed |
| CN-103610676-A | Application of 4-((pyridine-3-carbonyl)-amino)-butyric acid or salt thereof in preparation of medicament for treating male sexual erectile dysfunction disease | ZHEJIANG CANDORLY PHARMACEUTICAL CO LTD | 2014-03-05 | — | — | CN | claimed |
| WO-2013168019-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF NEUROPATHIC PAIN | KANDULA MAHESH (IN) | 2013-11-14 | — | — | WO | claimed |
| EP-1756310-B1 | Method for detecting polymorphisms in the ABCB1 gene associated with a lack of response to a CNS-active medicament and medicament comprising an ABCB1 inhibitor for use in the treatment of CNS related diseases. | MAX PLANCK GESELLSCHAFT (DE) | 2012-12-05 | — | — | EP | claimed |
| US-20100189819-A1 | NEURO-DEGENERATIVE INHIBITOR, NEURO-ENDOCRINE MODULATOR, AND NEURO-CEREBRAL METABOLISM ENHANCER | INTRATHERAPIES LLC (US) | 2010-07-29 | — | — | US | claimed |
| EP-2155261-A1 | SENSORY FEEDBACK-BASED METHOD FOR DETERMINING THE BIOAVAILABILITY OF ORALLY ADMINISTERED DIETARY SUPPLEMENTS | Northern Innovations And Formulations Corp. (CA) | 2010-02-24 | — | — | EP | claimed |
| WO-2008138099-A1 | SENSORY FEEDBACK-BASED METHOD FOR DETERMINING THE BIOAVAILABILITY OF ORALLY ADMINISTERED DIETARY SUPPLEMENTS | MULTI FORMULATIONS LTD. (CA) | 2008-11-20 | — | — | WO | claimed |
| US-20080276732-A1 | INDICATOR FOR ORALLY ADMINISTERED COMPOSITIONS | MULTI FORMULATIONS LTD. (CA) | 2008-11-13 | — | — | US | claimed |
| WO-2008100083-A1 | A COMPOSITION OF THE INJECTABLE AGENTS FOR TISSUES REPAIRE CONTAINING MESENCHYMAL STEM CELLS AND OPTIMIZED CULTURE MEDIA | PROSTEMICS CO., LTD. (KR) | 2008-08-21 | — | — | WO | claimed |
| WO-2004032916-A1 | A COMPOSITION COMPRISING SELEGELINE, PROCAINE, VINPOCETINE, TRIMETHYLGLYCINEAN AND A N-GABA INGREDIENT FOR TREATING NEURODEGENERATIVE DISORDERS | UNIFUND CORPORATION LIMITED (GB) | 2004-04-22 | — | — | WO | claimed |
| US-20040067986-A1 | Neuro-degenerative inhibitor, neuro-endocrine modulator, and neuro-cerebral metabolism enhancer | UNIFUND CORPORATION | 2004-04-08 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250019345-A1 | NEW CANNABINOID-GABAPENTINOID CONJUGATES AND USES THEREOF | CNR2, CNR1, GABRA4 | EPHX2 3566/4885KMT2A 2600/4885RAB9A 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.